EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Design and Evaluation of Next-Generation HIV Genotyping for Detection of Resistance Mutations to 28 Antiretroviral Drugs Across 5 Major Classes Including Lenacapavir

Sung Yong Park, Christian Takayama, Jenica Ryu, Martin Sattah, Zachariah Badii, Ju Won Kim iD, Robert W Shafer iD, Pamina M Gorbach iD, Ha Youn Lee iD

Clinical Infectious Diseases · 24.12.2025 · 81 (5) · e360-e369

DOI: 10.1093/cid/ciaf458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 19.08.2025. Verfasst von Sung Yong Park und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Drug Resistance, Viral, HIV Infections, Genotyping Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The emergence and spread of human immunodeficiency virus (HIV) drug-resistant strains present a major barrier to effective lifelong antiretroviral therapy. The anticipated rise in long-acting subcutaneous lenacapavir (LEN) use, along with the increased risk of transmitted resistance and pre-exposure prophylaxis–associated resistance, underscore the urgent need for advanced genotyping methods to enhance clinical care and prevention strategies.

Methods

We developed the portable HIV genotyping (PHG) platform, which combines cost-effective next-generation sequencing with cloud computing to screen for resistance to 28 antiretroviral drugs across 5 major classes, including LEN. We analyzed 3 study cohorts and compared our drug-resistance findings with standard-care testing results and high-fidelity sequencing data obtained through unique molecular identifier (UMI) labeling.

Results

PHG identified 2 major LEN-resistance mutations in 1 participant, confirmed by an additional independent sequencing run. Across 3 study cohorts, PHG consistently detected the same drug-resistance mutations as standard-care genotyping and high-fidelity UMI labeling in most tested specimens. PHG's 10% limit of detection minimized false-positive results and enabled identification of minority variants with less than 20% frequency, pointing to underdiagnosis of drug resistance in clinical care. Furthermore, PHG identified linked cross-class resistance mutations, confirmed by UMI labeling, including linked cross-resistance in a participant who reported use of long-acting cabotegravir and rilpivirine. We also observed multiyear persistence of linked cross-class resistance mutations.

Conclusions

PHG demonstrates significant improvements over standard-care HIV genotyping, offering deeper insights into LEN resistance, minority variants, and cross-class resistance using a low-cost, high-throughput portable sequencing technology and publicly available cloud computing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

High-Throughput Nucleotide SequencingDrug Resistance, ViralHIV InfectionsGenotyping TechniquesMutationHIV-1Anti-HIV AgentsAnti-Retroviral AgentsHumansGenotypeAcetamidesIndazoles

Stichwörter der Autor:innen

HIV resistancecloud computinglenacapavir resistanceportable next-generation sequencing

Substanzen

Anti-HIV AgentsAnti-Retroviral AgentslenacapavirAcetamidesIndazoles

Autor:innen und Institutionen

  • Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Department of Family Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Rand Schrader Clinic, Los Angeles General Medical Center, Los Angeles, California, USA.
  • Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
  • Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, USA.

ORCID-Profile: Ju Won Kim, Robert W Shafer, Pamina M Gorbach, Ha Youn Lee

Förderung

  • NIAID NIH HHS
  • NIDA NIH HHS

Zitieren

APA

Park, S. Y., Takayama, C., Ryu, J., Sattah, M., Badii, Z., Kim, J. W., Shafer, R. W., Gorbach, P. M., & Lee, H. Y. (2025). Design and Evaluation of Next-Generation HIV Genotyping for Detection of Resistance Mutations to 28 Antiretroviral Drugs Across 5 Major Classes Including Lenacapavir. Clinical Infectious Diseases, 81(5), e360-e369. https://doi.org/10.1093/cid/ciaf458

Vancouver

Park SY, Takayama C, Ryu J, Sattah M, Badii Z, Kim JW, et al. Design and Evaluation of Next-Generation HIV Genotyping for Detection of Resistance Mutations to 28 Antiretroviral Drugs Across 5 Major Classes Including Lenacapavir. Clinical Infectious Diseases. 2025;81(5):e360-e369. doi:10.1093/cid/ciaf458

BibTeX
@article{Park2025,
  author = {Park, Sung Yong and Takayama, Christian and Ryu, Jenica and Sattah, Martin and Badii, Zachariah and Kim, Ju Won and Shafer, Robert W and Gorbach, Pamina M and Lee, Ha Youn},
  title = {Design and Evaluation of Next-Generation HIV Genotyping for Detection of Resistance Mutations to 28 Antiretroviral Drugs Across 5 Major Classes Including Lenacapavir},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {81},
  number = {5},
  pages = {e360--e369},
  doi = {10.1093/cid/ciaf458}
}
Kostenlos starten →